GT201200319A - Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico - Google Patents

Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico

Info

Publication number
GT201200319A
GT201200319A GT201200319A GT201200319A GT201200319A GT 201200319 A GT201200319 A GT 201200319A GT 201200319 A GT201200319 A GT 201200319A GT 201200319 A GT201200319 A GT 201200319A GT 201200319 A GT201200319 A GT 201200319A
Authority
GT
Guatemala
Prior art keywords
rent
group
cicloalquil
alquilo
cicloalquilo
Prior art date
Application number
GT201200319A
Other languages
English (en)
Inventor
Sylvain Cote-Des-Combes
Jacques Froissant
Jean-Francois Gilbert
Frank Marguet
Christophe Pacaud
Frèderic Puech
Antoine Ravet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697541&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200319(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200319A publication Critical patent/GT201200319A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LOS COMPUESTOS CORRESPONDIENTES A LA FÓRMULA GENERAL (I) EN LA QUE R2 REPRESENTA UN GRUPO ALQUILO C1-10-ALQUILO, C3-10, CICLOALQUIL C3-7-CICLOALQUIL-ALQUILO C1-6-ALQUILO, C1-6-ALQUILO-C3-7-CICLOALQUILO , CICLOALQUILO C3-7-CICLOALQUILO-C3-7-CICLOALQUILO, C1-6-ALQUILTIO-C-1-10-ALQUILO, C1-6-ALCOXI-C1-10-ALQUILO, HIDROXI-ALQUILO C1-10-ALQUILO, HIDROXI-ALQUILO C1 -6-ALQUILO-C3-7-CICLOALQUIL-ALQUILO C1-6-ALQUILO, C3-HIDROXI-10-CICLOALQUILO, ALQUILO C1-10 O CICLOALQUILO C3-FLUOROALQUILO-10-FLUOROCYCLOALQUIL, UN GRUPO HETEROCÍCLICO OPCIONALMENTE SUSTITUIDO, UN GRUPO ALQUILO C1-10-ALQUILO SUSTITUIDO CON UN GRUPO HETEROCÍCLICO OPCIONALMENTE SUSTITUIDOXE REPRESENTA UN GRUPO ELEGIDO ENTRE HIDRÓGENO, FLÚOR, CLORO Y ÁTOMOS DE BROMO O UN GRUPO ALQUILO C1-6-ALQUILO, C3-7-CICLOALQUILO, C3-7-CICLOALQUIL-ALQUILO C1-6-ALQUILO, C1-6-FLUOROALQUILO O CIANO Y R7 REPRESENTA UN GRUPO ARILO TAL COMO FENILO O NAFTILO, OPCIONALMENTE SUSTITUIDO CON UNO O MÁS SUSTITUYENTES, EN FORMA DE LA BASE O DE UNA SAL DE ADICIÓN DE ÁCIDO. EL USO TERAPÉUTICO.
GT201200319A 2010-06-03 2012-11-27 Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico GT201200319A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1054372A FR2960876B1 (fr) 2010-06-03 2010-06-03 Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
GT201200319A true GT201200319A (es) 2014-01-17

Family

ID=42697541

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200319A GT201200319A (es) 2010-06-03 2012-11-27 Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico

Country Status (38)

Country Link
US (2) US8791119B2 (es)
EP (1) EP2588480B1 (es)
JP (1) JP5995841B2 (es)
KR (1) KR20130113928A (es)
CN (1) CN103168041B (es)
AR (1) AR081832A1 (es)
AU (1) AU2011268651B2 (es)
BR (1) BR112012030697A2 (es)
CA (1) CA2801154C (es)
CL (1) CL2012003360A1 (es)
CO (1) CO6602113A2 (es)
CR (1) CR20120595A (es)
CY (1) CY1118512T1 (es)
DK (1) DK2588480T3 (es)
DO (1) DOP2012000296A (es)
EA (1) EA201291364A1 (es)
EC (1) ECSP12012322A (es)
ES (1) ES2603420T3 (es)
FR (1) FR2960876B1 (es)
GT (1) GT201200319A (es)
HR (1) HRP20161494T1 (es)
HU (1) HUE030650T2 (es)
IL (1) IL223364A (es)
LT (1) LT2588480T (es)
MA (1) MA34360B1 (es)
MX (1) MX2012014084A (es)
NI (1) NI201200176A (es)
NZ (1) NZ603947A (es)
PE (1) PE20130259A1 (es)
PL (1) PL2588480T3 (es)
PT (1) PT2588480T (es)
SG (1) SG186143A1 (es)
SI (1) SI2588480T1 (es)
TN (1) TN2012000520A1 (es)
TW (1) TWI487707B (es)
UY (1) UY33428A (es)
WO (1) WO2011161537A2 (es)
ZA (1) ZA201209071B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
UY35834A (es) * 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
JP6307989B2 (ja) * 2014-04-02 2018-04-11 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
CN110709523B (zh) * 2017-04-12 2023-07-11 豪夫迈·罗氏有限公司 使用经pictet spengler反应获得的加标签的核苷的测序反应方法
JP2020528062A (ja) * 2017-07-27 2020-09-17 江蘇恒瑞医薬股▲ふん▼有限公司 ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
TW202412758A (zh) * 2022-06-29 2024-04-01 香港商英矽智能科技知識產權有限公司 Fgfr2與fgfr3抑制劑及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150991B1 (en) 1999-02-01 2004-04-07 University of Virginia Patent Foundation Compositions for treating inflammatory response
MXPA04002243A (es) * 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
ATE428711T1 (de) 2003-12-11 2009-05-15 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
GB0328900D0 (en) 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
US8304408B2 (en) * 2007-05-24 2012-11-06 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
NZ582871A (en) 2007-07-27 2011-09-30 Sanofi Aventis 1,2,3,4-Tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5- tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof
EP2229395A1 (en) * 2008-01-17 2010-09-22 Grünenthal GmbH Substituted sulfonamide derivatives
WO2009097515A2 (en) * 2008-01-30 2009-08-06 Wyeth [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
CN103168041B (zh) 2015-08-26
MA34360B1 (fr) 2013-07-03
CO6602113A2 (es) 2013-01-18
CA2801154A1 (en) 2011-12-29
ECSP12012322A (es) 2013-03-28
CL2012003360A1 (es) 2013-04-01
US9233965B2 (en) 2016-01-12
SG186143A1 (en) 2013-01-30
DK2588480T3 (en) 2016-12-12
EA201291364A1 (ru) 2013-05-30
HRP20161494T1 (hr) 2016-12-16
AU2011268651A1 (en) 2012-12-20
PL2588480T3 (pl) 2017-08-31
NI201200176A (es) 2013-02-06
TWI487707B (zh) 2015-06-11
FR2960876A1 (fr) 2011-12-09
SI2588480T1 (sl) 2016-12-30
DOP2012000296A (es) 2013-02-28
CA2801154C (en) 2018-01-09
KR20130113928A (ko) 2013-10-16
JP2013527226A (ja) 2013-06-27
UY33428A (es) 2011-12-30
TN2012000520A1 (en) 2014-04-01
PE20130259A1 (es) 2013-03-22
US8791119B2 (en) 2014-07-29
CN103168041A (zh) 2013-06-19
AU2011268651B2 (en) 2016-09-01
FR2960876B1 (fr) 2012-07-27
MX2012014084A (es) 2013-01-29
TW201202248A (en) 2012-01-16
HUE030650T2 (en) 2017-05-29
CY1118512T1 (el) 2017-07-12
CR20120595A (es) 2013-01-03
PT2588480T (pt) 2016-11-21
WO2011161537A2 (en) 2011-12-29
WO2011161537A3 (en) 2012-03-01
EP2588480B1 (en) 2016-08-17
US20140336189A1 (en) 2014-11-13
ES2603420T3 (es) 2017-02-27
NZ603947A (en) 2014-12-24
BR112012030697A2 (pt) 2019-09-24
EP2588480A2 (en) 2013-05-08
AR081832A1 (es) 2012-10-24
LT2588480T (lt) 2016-12-12
ZA201209071B (en) 2014-02-26
US20130090340A1 (en) 2013-04-11
IL223364A (en) 2015-06-30
JP5995841B2 (ja) 2016-09-21

Similar Documents

Publication Publication Date Title
GT201200319A (es) Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
CU20140110A7 (es) Compuestos heterocíclicos como inhibidores de mek
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
AR097931A1 (es) Derivados de diazacarbazol como ligandos de tau para pet
AR104326A1 (es) Compuestos nucleósidos 5-sustituidos
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20130779A1 (es) Pirimidinas y triazinas condensadas y su uso
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
ECSP11010889A (es) INHIBIDORES DE cMET
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
BRPI0911422B8 (pt) compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
UY33801A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
CR20150254A (es) Compuestos quimicos
CR11866A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
CR20120033A (es) Derivados de 5-fluoro-2-oxopirimidina-1-(2h) carboxilato.
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
NI201000023A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica.
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.